Lanxess AG
LXS.DE · XETRA
Company research
LANXESS Aktiengesellschaft is a leading German specialty chemicals company headquartered in Cologne, Germany, with roots tracing back to 1863 and established as an independent entity in 2004 following a spin-off from Bayer AG. The company develops, manufactures, and markets chemical intermediates, additives, specialty chemicals, and consumer protection products across three core segments: Advanced Industrial Intermediates, Specialty Additives, and Consumer Protection. With approximately 11,700 employees operating in 32 countries and revenues of EUR 5.7 billion in 2025, LANXESS serves a broad range of industries including automotive, construction, agrochemicals, electronics, pharmaceuticals, and water treatment. Listed on the Deutsche Börse and a constituent of the MDAX index, LANXESS is also recognized for its sustainability credentials, being included in the Dow Jones Sustainability Index and FTSE4Good.
Research reports
Equity research note discussing a weak Q2 2025 performance but framing the share price reaction as an “accumulation opportunity,” underpinned by valuation work using forward EV/EBITDA and EV/EBIT multiples for 2025–2026. The analysis argues that cost-saving measures and medium-term earnings normalization should support upside from current levels, while highlighting ongoing cyclical demand weakness and execution on restructuring as key risks.
Scope Ratings GmbH · August 4, 2025LANXESS AG Issuer Rating ReportComprehensive credit rating report in which Scope upgrades LANXESS’ issuer rating to BBB with a Stable Outlook, citing ongoing deleveraging, portfolio optimization, and the FORWARD! cost-savings program as supporting a gradual recovery of EBITDA margins toward 10–11 percent over the next three years. The report emphasizes LANXESS’ strong positions in several specialty-chemical niches and improved end-market diversification, but flags still-elevated leverage, significant exposure to cyclical industries, and reliance on asset disposals for deleveraging as core risk factors.